Meeting
2022 ASCO Annual Meeting
Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
Authors
Chau T. Dang
Memorial Sloan Kettering Cancer Center, New York, NY
Chau T. Dang , Sara M. Tolaney , Fauzia Riaz , Antoinette R. Tan , Katherine H. R. Tkaczuk , Anthony Francis Yu , Jennifer Liu , Anita M. Fung , Anna Yang , Bann-mo Day , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Care Delivery
Clinical Trial Registration Number
NCT04395508
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1515)
DOI
10.1200/JCO.2022.40.16_suppl.1515
Abstract #
1515
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
First Author: Veronique Debien
Poster
2017 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
First Author: Ines Maria Vaz Duarte Luis
Poster
2022 ASCO Annual Meeting
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
First Author: Brian Andrew Van Tine
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
First Author: Joleen M. Hubbard